Skip to content
The Policy VaultThe Policy Vault

Arcalyst (rilonacept) — United Healthcare

Cryopyrin-Associated Periodic Syndromes (CAPS) including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS)

Initial criteria

  • Diagnosis of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS)

Reauthorization criteria

  • Documentation of positive clinical response to Arcalyst therapy

Approval duration

12 months